Delfi Diagnostics has raised $225m in a Series B financing round for the development of a globally accessible portfolio of liquid biopsy tests.

Led by DFJ Growth, the financing round saw participation from Initiate Ventures, PTX Capital, Brown Advisory, Eli Lilly and Company, Point72, Open Field Capital, and Point Field Partners.

The round also included the company’s existing investors, namely Samsara BioCapital, AV8 Ventures, Menlo Ventures, OrbiMed, Osage University Partners, Rock Springs Capital, and funds and accounts advised by T Rowe Price Associates.

Illumina Ventures, Foresite Capital, Cowen Healthcare Investments, Northpond Ventures and Windham Venture Partners also participated.

Delfi Diagnostics previously raised $100m in a Series A round in last January.

The company intends to use the proceeds from the latest funding round to support the continued development and commercialisation of blood tests for early detection of single cancer and multi-cancer, as well as monitoring treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

It has built a platform for developing liquid biopsy applications through a proprietary scalable whole genome fragmentation approach.

As Delfi’s platform analyses the cell-free DNA fragments across the entire genome, it enables a low-cost, single and straightforward laboratory process for any test developed.

Delfi CEO and founder Victor Velculescu said: “Cancer is a global public health problem and addressing it requires a solution that is accessible around the world.

“We believe our approach is uniquely capable of delivering high-performing, cost-effective, and clinically relevant tests for multiple applications to meet the needs of patients and providers everywhere.”

Currently, the company is validating the technology in a CASCADE-LUNG prospective trial, which has enrolled 15,000 subjects, for the detection of lung and other cancers in the early stages.

Additionally, it is working with many research institutions to develop new applications for detecting other cancer types, early detection of multi-cancer and treatment monitoring.